MedKoo Cat#: 532170 | Name: LY-465608

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LY-465608 is a PPAR Agonist which inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice.

Chemical Structure

LY-465608
LY-465608
CAS#328918-26-9

Theoretical Analysis

MedKoo Cat#: 532170

Name: LY-465608

CAS#: 328918-26-9

Chemical Formula: C28H27NO5

Exact Mass: 457.1889

Molecular Weight: 457.53

Elemental Analysis: C, 73.51; H, 5.95; N, 3.06; O, 17.48

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
LY-465608 ; LY 465608; LY465608.
IUPAC/Chemical Name
2-methyl-2-[4-[2-[5-methyl-2-(4-phenylphenyl)-1,3-oxazol-4-yl]ethoxy]phenoxy]propanoic acid
InChi Key
JDJHTJNBMZSSLK-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H27NO5/c1-19-25(17-18-32-23-13-15-24(16-14-23)34-28(2,3)27(30)31)29-26(33-19)22-11-9-21(10-12-22)20-7-5-4-6-8-20/h4-16H,17-18H2,1-3H3,(H,30,31)
SMILES Code
CC(OC1=CC=C(OCCC2=C(C)OC(C3=CC=C(C4=CC=CC=C4)C=C3)=N2)C=C1)(C)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 457.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Guo Y, Jolly RA, Halstead BW, Baker TK, Stutz JP, Huffman M, Calley JN, West A, Gao H, Searfoss GH, Li S, Irizarry AR, Qian HR, Stevens JL, Ryan TP. Underlying mechanisms of pharmacology and toxicity of a novel PPAR agonist revealed using rodent and canine hepatocytes. Toxicol Sci. 2007 Apr;96(2):294-309. PubMed PMID: 17255113. 2: Zuckerman SH, Kauffman RF, Evans GF. Peroxisome proliferator-activated receptor alpha,gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice. Lipids. 2002 May;37(5):487-94. PubMed PMID: 12056591. 3: Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR Jr, Ogilvie KM, Liu S, Kauffman RF. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes. 2002 Apr;51(4):1083-7. PubMed PMID: 11916929.